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Objectives. We sought to determine the clinical, angiographic,
treatment and outcome correlates of the intermediate-term cost of
caring for patients with suspected coronary artery disease (CAD).
Background. To adequately predict medical costs and to com-
pare different treatment and cost reduction strategies, the deter-
minants of cost must be understood. However, little is known
about the correlates of costs of treatment of CAD in heterogenous
patient populations that typify clinical practice.
Methods. From a consecutive series of 781 patients undergoing
cardiac catheterization in 1992 to 1994, we analyzed 44 variables
as potential correlates of total (direct and indirect) in-hospital,
12- and 36-month cardiac costs.
Results. Mean (6SD) patient age was 65 6 10 years; 71% were
men, and 45% had multiple vessel disease. The initial treatment
strategy was medical therapy alone in 47% of patients, percuta-
neous intervention (PI) in 30% and coronary artery bypass graft
surgery (CABG) in 24%. The 36-month survival and event-free
(death, infarction, CABG, PI) survival rates were 89.6 6 0.2% and
68.4 6 0.4%, respectively. Median hospital and 36-month costs
were $8,301 and $28,054, respectively, but the interquartile ranges
for both were wide and skewed. Models for loge costs were
superior to those for actual costs. The variances accounted for by
the all-inclusive models of in-hospital, 12- and 36-month costs
were 57%, 60% and 71%, respectively. Baseline cardiac variables
accounted for 38% of the explained in-hospital costs, whereas
in-hospital treatment and complication variables accounted for
53% of the actual costs. Noncardiac variables accounted for only
9% of the explained costs. Over time, complications (e.g., late
hospital admission, PI, CABG) and drug use to prevent compli-
cations of heart transplantation became more important, but
many baseline cardiac variables retained their importance.
Conclusions. 1) Variables readily available from a comprehen-
sive cardiovascular database explained 57% to 71% of cardiac
costs from a hospital perspective over 3 years of care; 2) the initial
revascularization strategy was a key determinant of in-hospital
costs, but over 3 years, the initial treatment become somewhat less
important, and late complications became more important deter-
minants of costs.
(J Am Coll Cardiol 1998;31:1306–13)
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To meet the challenge of reducing medical resource utilization
without jeopardizing the quality of patient outcomes, knowl-
edge of the determinants of long-term cost is imperative (1).
Cardiovascular disease and its management are prime targets
for cost reduction initiatives because of the high prevalence
and cost of the disease ($128 billion in the United States alone
in 1994 [2]). Judgments regarding cost and quality of outcome
with different treatment strategies and from different providers
are pivotal. Data from randomized, controlled trials minimize
many forms of bias but are typically limited to selected patient
groups (2,4). Evaluation from nonrandomized sources requires
the capacity to appropriately “adjust” for differences in base-
line variables. Data identifying key determinants of long-term
costs in patients with coronary artery disease (CAD) are limited.
Although several carefully performed cost studies in this
area have been reported (5,6), many have serious limitations
(7). These limitations include use of charges rather than actual
costs (8–10), estimated unit costs rather than actual costs
(11,12), administrative datasets not including key variables
(10), small number of patients (13), lack of long-term perspec-
tive (14,15), failure to capture many outpatient costs (12) and
less than optimal statistical modeling (invalid assumption of
normality of cost distribution, lack of validation testing or
specification of degree of model fit) (9,13–15).
Therefore, we sought to carefully evaluate the major deter-
minants of cardiac costs over a 2- to 3-year period in a well
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characterized patient cohort in whom all cardiac costs from a
provider perspective could be ascertained.
Methods
Patients. All patients undergoing cardiac catheterization
with coronary angiography from January 1, 1992 through
December 31, 1994 who responded to a query as to whether,
since January 1992, they had received, and were continuing to
receive, all cardiac care at our institution and who consented to
participate in the study were eligible for study inclusion. If a
patient was alive and had exited our care system, their data
were censored at the time of exit. Treatment recommendations
were made by the patient’s clinic physician. Baseline, treat-
ment and in-hospital clinical outcome and all cost data were
recorded prospectively in several hospital databases that were
merged for the purposes of the study. Patients treated with
percutaneous or surgical revascularization had their long-term
clinical outcome tracked prospectively by means of written
questionnaire, telephone contact or direct contact with refer-
ring physicians or family members. Patients treated medically
had their clinical outcome evaluated retrospectively using
methodology nearly identical to that for the other groups. Cost
and clinical data were available for all eligible patients.
Method of determining costs. Cost data were downloaded
from the hospital and outpatient cost accounting system (Tran-
sition System, Inc.), a previously described commercially avail-
able system that calculates total (direct and indirect; hospital,
outpatient and physician) cost on a per-patient basis (16). Not
captured in the system were outpatient medication costs, which
were obtained by 1) tracking all cardiac medications taken by
patients on an every 2-month basis and calculating the costs on
the basis of direct pharmacy costs at our center at the time that
medications were taken; and 2) tracking costs from other
institutions, which were obtained as necessary and estimated
using institution-specific cost/charge ratios (Aspen Healthcare
Metrics, Inc., 1994). All dollar costs were devalued to January
1992 dollars using the health care price index (17), and the
future value of money was considered using the consumer
price index.
Statistical analysis. Continuous time-independent data
are described as mean value 6 SD or median and interquartile
range, depending on the normality of their distribution. Cate-
goric data are presented as a percent. Standard errors of the
estimate are provided for Kaplan-Meier survivor analyses.
Both cost and loge cost at the time of hospital discharge and
at 12 and 36 months after initial cardiac catheterization were
tabulated. To determine predictive models for these six end
points, univariable and multivariable modeling was performed
using 36 candidate preprocedural covariates, allowing entry
into the multivariable model only those variables that corre-
lated with the dependent variable at p , 0.05. Explanatory
models using 44 pretreatment and posttreatment candidate
variables for the in-hospital and 12- and 36-month outcomes
were also developed. Length of stay was not included as a
potential covariate because it is, for the most part, not an
independent variable; rather, length of stay is directly related
to complications, and its inclusion would therefore eliminate
variables that might provide more direct insight into the
determinants of costs. These models were internally validated
using a tenfold cross validation, using a randomly selected 80%
sample for fitting and the remaining 20% of the sample for
testing to assess the extent to which the predictive accuracy of
the models was overly optimistic (18). The degree of model fit
was assessed by evaluating the adjusted r2 coefficient.
Potential covariates, definitions and conventions. Selected
preprocedural candidate covariates are shown in Table 1. In
addition, the following variables were considered: body mass
index (weight/height2), chronic obstructive pulmonary disease
requiring medication, diagnosed CAD (see Other definitions),
height, previous stroke or transient ischemic attack, sinus
rhythm, stable angina, symptomatic peripheral vascular dis-
ease, valvular heart disease (moderate or severe stenosis or
regurgitation) and weight.
For the explanatory models, the following post procedural
variables were also considered: initial treatment and follow-up
coronary artery bypass graft surgery (CABG), cardiac cathe-
terization, death, hospital admission, myocardial infarction,
outpatient medication use (see Other definitions), percutane-
ous intervention (PI) and use of cardiac rehabilitation.
Other definitions. Arrhythmia as indication for cardiac cath-
eterization was defined as catheterization principally to exclude
significant CAD as an underlying cause, or complicating
feature, of supraventricular or ventricular arrhythmia. Outpa-
tient medications included use of angiotensin-converting en-
zyme inhibitors, antiarrhythmic agents (Vaughn-Williams class
Ia, Ic, amiodarone or sotolol), aspirin, beta-adrenergic block-
ing agents, calcium channel antagonists, digitalis, diuretic
agents, statin-class lipid-lowering agents and warfarin at any
time for $2 months during the first 12 months after catheter-
ization and were coded separately. Significant CAD was de-
fined as a history of myocardial infarction, previous PI or
$50% diameter stenosis in a potentially bypassable artery
(.1.5-mm diameter by visual estimate). Urgent/emergency cath-
eterization status was defined as those procedures that, on the
basis of clinical indication, should be performed on the same
day as presentation (urgent) or immediately (emergency) as
opposed to an elective procedure.
Subset analyses. Prespecified subgroup analyses intended
to provide insight into either the comparability of these data
with cost data from randomized, controlled trials or into
potential areas for cost reduction were risk-adjusted time-
related costs of 1) PI and CABG for patients with multiple-
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
CCS 5 Canadian Cardiovascular Society
PI 5 percutaneous intervention
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vessel disease; and 2) initial medical therapy or PI for patients
with one- or two-vessel disease. Covariates were derived from
analyses shown later in Tables 3 to 8, modified as necessary for
the subgroups studied. Covariates used in the models are
presented in the Appendix.
Results
Initial treatment and outcome. Medical therapy. After
catheterization, 239 of 364 patients referred for medical ther-
apy had significant coronary artery disease (Table 1). The
survival rates at 30 days and 1, 2 and 3 years for these 239
patients were 98.8 6 0.1%, 95.2 6 0.1%, 89.9 6 0.2% and
81.0 6 0.4%, respectively, and the infarct- and bypass-free
survival rates were 98.0 6 0.1%, 89.8 6 0.2%, 76.2 6 0.4% and
63.5 6 0.6%, respectively. At the latest follow-up visit, 79.2%
of patients had no angina, 13.3% had Canadian Cardiovascular
Society (CCS) class I or II angina, and 7.5% had CCS class III
or IV angina. Their resource utilization is described in Table 2;
their cumulative cost of cardiac care is shown in Figure 1; and
the distribution of their costs is shown in Figure 2. In addition,
17 patients underwent heart transplantation, 5 had primary
ventricular arrhythmias, 4 had primary valvular heart disease, 4
had coronary spasm, and 98 had suspected but no significant
CAD.
Percutaneous coronary revascularization. Two hundred
thirty-two patients had PI as their initial treatment after the
index catheterization. Their baseline characteristics are de-
Table 1. Patient Characteristics (by treatment group)
Study Cohort
All Pts Undergoing
Cath 1992–1994
(n 5 16,219)
Medicine*
(n 5 347)
PI
(n 5 232)
CABG
(n 5 185)
Total†
(n 5 781)
Age (yr) 65 6 11 64 6 10 66 6 10 65 6 10 62 6 11
CCS angina class
I or II 51% 48% 42% 48% NA
III or IV 26% 40% 38% 33% NA
Current smoker 16% 17% 21% 17% 22%
Diabetes mellitus 28% 26% 33% 29% 29%
Hypertension 67% 60% 71% 66% 62%
Male 67% 77% 72% 71% 70%
Major comorbidities
COPD 5% 7% 7% 6% 6%
Creatinine $2 mg% 8% 4% 2% 6% 5%
CVA/TIA 12% 8% 14% 11% 10%
PVOD 18% 17% 19% 18% 19%
Prior CABG 31% 25% 20% 27% 25%
Prior MI 45% 40% 42% 43% 43%
Prior VT/VF 7% 4% 3% 5% NA
LVEF ,40% 13% 12% 11% 12% 15%
Multivessel disease 29% 37% 89% 45% 52%
Jeopardy score (0–6) 1.3 6 1.5 2.3 6 1.3 3.8 6 1.4 2.2 6 1 NA
Unstable angina 44% 49% 49% 47% NA
Hospital transfer 9% 17% 17% 13% 19%
Urgent/emergency cath 33% 46% 55% 41% NA
*Excludes data for transplant recipients. †Includes data for transplant recipients. Data presented are mean value 6
SD or percent of patients. CABG 5 coronary artery bypass graft surgery; Cath 5 catheterization; CCS 5 Canadian
Cardiovascular Society; COPD 5 chronic obstructive pulmonary disease; CVA 5 cerebrovascular accident (stroke);
LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; NA 5 not available; PI 5 percutaneous
intervention; Pts 5 patients; PVOD 5 peripheral vascular obstructive disease; TIA 5 transient ischemic (neurologic)
attack; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
Table 2. Resource Utilization After Initial Hospital Stay*
Medicine† PI CABG Total
CABG 7.7% 15.5% 0.6% 8.4%
Cardiac cath 25.6% 48.9% 17.1% 31.1%
Cardiac rehabilitation 5.6% 15.1% 24.3% 16.7%
Hospital admission 36.5% 49.4% 27.8% 38.5%
PI 9.4% 26.8% 5.0% 13.8%
Pharmaceutical agent (selected)
Aspirin 88% 97% 94% 93%
ACE inhibitors 15% 18% 26% 24%
Antiarrhythmic agents 7% 6% 9% 8%
Beta-blockers 20% 38% 24% 32%
Calcium channel blockers 38% 57% 28% 46%
Statin-class lipid-lowering
agents‡
18% 23% 17% 24%
Nitrates 20% 29% 17% 33%
Warfarin 7% 4% 13% 8%
*At any time during follow-up (27 6 12 months). †Excludes patients without
coronary artery disease and transplant recipients. ‡3-hydroxy-3-methylglutargl-
coenzyme A inhibitors (e.g., lovastatin). ACE 5 angiotensin-converting enzyme;
other abbreviations as in Table 1.
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scribed in Table 1. The primary PI was balloon angioplasty in
68.6%, stenting in 12.3%, directional atherectomy in 10.6%,
rotational atherectomy in 6.8% and excimer laser in 1.7%.
Technical success without death, infarction or need for
CABG was obtained in 94.5% of patients. Overall survival and
infarct- and bypass-free survival rates at 30 days and 1, 2 and 3
years were 98.9 6 0.1%, 98.2 6 0.1%, 95.4 6 0.2% and 94.1 6
0.2%, and 92.9 6 0.2%, 82.5 6 0.3%, 77.8 6 0.3% and 71.8 6
0.4%, respectively. At latest follow-up, 84.9% had no angina,
12.3% had CCS class I or II angina, and 1.4% had CCS class III
or IV angina. Their resource utilization, cumulative cost of
cardiac care and cost distribution are shown in Table 2 and
Figures 1 and 2, respectively.
Bypass surgery. One hundred eighty-five patients had
CABG as their initial therapy after catheterization. Seventy-
one percent received one or more arterial conduits, and 10%
had concomitant valve surgery. Their survival and infarct- and
bypass-free survival rates at 30 days and 1, 2 and 3 years were
97.5 6 0.1%, 94.2 6 0.2%, 93.0 6 0.2% and 91.4 6 0.3%, and
92.1 6 0.2%, 86.4 6 0.3%, 85.2 6 0.3% and 81.4 6 0.4%,
respectively. At the time of latest follow-up, 87.7% had no
angina, 10.4% had CCS class I or II angina, and 1.9% had CCS
class III or IV angina. Their resource utilization, cumulative
costs and distribution of costs are shown in Table 2 and Figures
1 and 2, respectively.
Patients without demonstrable heart disease. Ninety-eight
patients had “insignificant” or no demonstrable CAD and were
treated medically. Their survival and infarct- and bypass-free
survival rates at 1, 2 and 3 years were 99.3 6 0.1, 99.3 6 0.1 and
99.3 6 0.1, and 97.3 6 0.2%, 94.7 6 0.3% and 92.4 6 0.4%,
respectively. At latest follow-up, 83.6% had no angina, 16.4%
had CCS class I or II angina, and none had CCS class III or IV
angina. Over the 25 6 11-months follow-up period, 10.3%
required hospital admission for cardiac indications, and 6.0%
required repeat catheterization. Their median cardiac costs at
1, 2 and 3 years after discharge were $960, $1,035 and $4,415,
respectively. Thirty-eight patients had one or more abnormal
functional tests before catheterization. The 3-year postdis-
charge costs for these patients was only $522 per patient.
Transplant recipients. Seventeen patients underwent car-
diac catheterization after heart transplantation or underwent
transplantation within 12 months of catheterization. One, 2
and 3 years after index catheterization, 95.3%, 88.3% and
88.3% were alive, and their cardiac costs were $56,532 6
$68,317, $51,248 6 $50,100; and $83,261 6 $48,216, respec-
tively. These costs were in large part due to the cost of the
hospital stay for transplantation ($77,786 6 $45,464) and the
cost of outpatient medications ($28,221 6 $18,701).
Long-term follow-up. The average time of clinical follow-up
in survivors was 27 6 12 months. Ten patients (1.3%) were lost
to follow-up, and 69 (8.8%) left the clinic system for another
medical care group at 23 6 10 months. Patients leaving the
clinic system less often had baseline creatinine levels $2.0
mg% (1.6% vs. 6.9%, p 5 0.007) and congestive heart failure
(4.3% vs. 10.6%, p 5 0.02), but were otherwise similar to
patients remaining in the system. Cost data through 12 months,
when most patients who eventually left were still in the system,
were nearly identical for those who eventually left and those
who did not. The number of patients thus eligible for the
in-hospital and 1- and 3-year follow-up analyses were 781, 684
and 296, respectively.
Figure 1. Median actual costs over time for patients treated with an
initial strategy of medical therapy alone (squares), PI (circles) or
CABG (triangles). Costs for transplant recipients are excluded.
Figure 2. Distribution of cost sources for patients
treated with initial treatment strategies of CABG, PI
PTCR or medical therapy alone (transplant recipients
excluded).
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Correlates of cost and loge cost. Correlates of loge cost are
provided in Tables 3 to 8. The corrections to the linear
regression models resulting from cross validation were gener-
ally small (that for pretreatment correlates of in-hospital cost
reduced r2 from 0.402 to 0.391 [Table 1]). For each analysis,
either the proportion of explained variance (r2) was less, or the
Studentized residuals’ variance (19) was greater, or both, for
models of cost compared with loge cost, indicating the latter’s
superiority (data not shown).
Overall predictive capacity, measured by the explained
variance (r2), was 35% to 55% for models with pretreatment
variables only and 57% to 71% for all-inclusive models.
Variables representing baseline cardiac status and the initial
treatment strategy dominated the models explaining in-
hospital cost. Over time, complications, reflected by variables
such as need for later hospital admission, PI or CABG, became
powerful correlates of overall cardiac cost.
Of the commonly predictive variables, most would be
available in a cardiovascular database. One, the jeopardy score
(20), is less commonly used. The number of diseased vessels,
closely related to the jeopardy score, could be substituted with
Table 3. Independent Pretreatment Correlates of In-Hospital
Loge Cost*
Cost Effect
(%)† 95% CI
$
Increment
Multiple
p Value‡
Jeopardy score 11.1/U 9.3 to 12.9 1,541/U , 0.001
MI ,2 wk before
catheterization
42.6 33.3 to 52.9 5,908 , 0.001
CHF 55.5 41.6 to 69.4 7,697 , 0.001
Arrhythmia indication 54.6 36.4 to 72.8 7,578 , 0.001
Prior CABG 214.5 218.5 to 210.5 22,009 , 0.001
Valvular heart disease 35.3 23.1 to 47.5 4,893 0.001
Catheterization status 15.1 9.9 to 20.3 2,098 0.001
Unstable angina 19.8 12.8 to 26.8 2,743 0.001
CAD 24.7 14.9 to 34.5 3,426 0.004
Hospital transfer 22.5 13.4 to 31.6 3,123 0.005
Creatinine $2 mg% 29.4 15.8 to 43.0 4,079 0.010
CCS angina class
III/IV
13.9 7.5 to 20.3 1,928 0.013
Positive stress test 210.8 215.6 to 26.0 21,496 0.025
*Constant 5 7.797; adjusted multiple r2 5 0.391. †See Appendix for
definition. ‡Univariate and multivariate p values for other selected variables:
age, p 5 0.02, p 5 0.94; chronic obstructive pulmonary disease, p 5 0.14, p 5
0.11; diabetes, p 5 0.01, p 5 0.77; left ventricular ejection fraction, p , 0.001,
p 5 0.18; height, p 5 0.007, p 5 0.08; male gender, p 5 0.32, p 5 0.16; number
of diseased vessels, p , 0.001, p 5 0.86; previous myocardial infarction, p 5 0.40,
p 5 0.09; symptomatic peripheral vascular obstructive disease, p 5 0.28, p 5
0.50; weight, p 5 0.27, p 5 0.23. CAD 5 coronary artery disease; CHF 5
congestive heart failure; CI 5 confidence interval; other abbreviations as in
Table 1.
Table 4. Overall Independent Correlates of In-Hospital Loge Cost*
Cost Effect
(%)† 95% CI
$
Increment
Multiple
p Value
Medical Rx 234.8 237.1 to 232.5 24,833 , 0.001
CABG 42.8 37.3 to 48.3 5,939 , 0.001
Arrhythmia indication 78.9 69.5 to 88.3 10,958 , 0.001
Recent MI 34.7 28.5 to 40.9 4,814 , 0.001
Creatinine $2 mg% 49.0 39.9 to 58.1 6,803 , 0.001
CHF 30.5 22.6 to 38.4 4,240 , 0.001
Cath status 11.4 7.8 to 15.0 1,579 0.001
Valvular heart disease 26.6 18.7 to 34.5 3,691 0.001
In-hospital MI 47.8 33.4 to 62.2 6,635 0.001
Positive stress test 211.1 214.8 to 27.4 21,537 0.002
CCS/angina III/IV 11.5 7.1 to 15.9 1,599 0.006
Unstable angina 12.1 7.4 to 16.8 1,680 0.008
Hospital transfer 12.5 6.5 to 18.5 1,741 0.031
*Constant 5 8.691; adjusted multiple r2 5 0.570. †See Appendix for
definition. Rx 5 treatment; other abbreviations as in Tables 1 and 3.
Table 5. Pretreatment Correlates of 12-Month Loge Cost*
Cost Effect
(%)† 95% CI
$
Increment
Multiple
p Value‡
CHF 49.7 35.4 to 64.0 12,138 , 0.001
CAD 36.8 24.1 to 49.5 8,999 0.001
Valvular heart disease 36.2 22.8 to 49.6 8,850 0.001
Creatinine $2 mg% 33.8 18.5 to 49.1 8,265 0.007
Recent MI 20.8 11.7 to 29.9 5,075 0.008
Cath status 13.6 8.1 to 19.1 3,313 0.008
Positive stress test 212.6 217.3 to 27.9 23,089 0.012
Unstable angina 15.1 8.1 to 22.1 3,700 0.013
Jeopardy score 7.3/U 4.4 to 10.2 1,788/U 0.014
Prior CABG 211.9 216.6 to 27.2 22,909 0.017
No. of diseased vessels 11.2/U 5.2 to 16.2 2,747/U 0.036
Arrhythmia indication 27.5 10.9 to 44.1 6,726 0.046
*Constant 5 8.328; adjusted multiple r2 5 0.330. †See Appendix for
definition. ‡Univariate and multivariate p values for pretreatment variables
correlated with loge cost during hospital stay not entering this model: angina
grade III/IV at baseline, p , 0.001, p 5 0.33; hospital transfer, p , 0.001, p 5
0.26. Abbreviations as in Tables 1 and 3.
Table 6. Overall Correlates of 12-Month Loge Cost*
Cost Effect
(%)† 95% CI
$
Increment
Multiple
p Value‡
Initial medical Rx 232.3 234.9 to 229.7 27,892 , 0.001
Transplant patient 140.1 127.4 to 152.8 34,256 , 0.001
Late hospital admission 34.3 29.3 to 39.3 8,385 , 0.001
Initial CABG 40.2 34.0 to 46.8 9,813 , 0.001
Unstable angina at baseline 16.5 12.2 to 20.8 4,030 , 0.001
MI ,2 wk before cath 20.6 15.3 to 25.9 5,024 , 0.001
Arrhythmia indication 41.6 30.2 to 53.0 10,162 , 0.001
Antiarrhythmic Rx 24.2 16.2 to 32.2 5,902 0.002
Baseline CHF 25.7 17.1 to 34.3 6,289 0.002
Late CABG 22.3 14.0 to 31.6 5,449 0.008
Baseline LV Function 2.3/U 1.4 to 3.2 567/U 0.014
Baseline creatinine $2 mg% 20.7 11.0 to 30.4 5,061 0.022
Use of cardiac rehabilitation 12.2 6.6 to 17.8 2,977 0.023
Diuretic Rx 9.3 4.7 to 13.9 2,263 0.034
*Constant 5 9.149; adjusted multiple r2 5 0.626. †See Appendix for
definition. ‡Univariate and multivariate p values for variables correlated with
loge cost during initial hospital stay not entering this model: angina class III/IV,
p , 0.001, p 5 0.26; baseline catheterization status, p , 0.001, p 5 0.20; hospital
transfer, p , 0.001, p 5 0.77; positive stress test at baseline, p , 0.001, p 5 0.13;
valvular heart disease, p , 0.001, p 5 0.17. LV 5 left ventricular; other
abbreviations as in Tables 1, 3 and 4.
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little loss of predictive capacity (e.g., adjusted r2 with number
of diseased vessels in the predictive model of loge in-hospital
cost reduced the adjusted r2 from 0.391 to 0.383).
For patients with multiple-vessel disease not treated med-
ically (n 5 274), CABG compared with PI led to an incremen-
tal cost, after consideration of the possible effect of baseline
variables noted in the Appendix, during the index hospitaliza-
tion and at 12 and 36 months of $4,796 6 $850 (p , 0.001),
$3,329 6 $2,087 (p 5 0.07) and $2,421 6 $3,152 (p 5 0.40),
respectively. There was no difference in the level of angina at
follow-up for the two groups.
For patients with one- or two-vessel disease not treated with
CABG (n 5 433), PI compared with initial medical therapy led
to incremental costs during the index hospital stay and at 12
and 36 months of $11,162 6 $1,371 (p , 0.001), $5,702 6 $979
(p , 0.001) and $5,004 6 $1,764 (p , 0.001), respectively.
However, patients treated medically less often had no angina
(80.1% vs. 85.7%, p 5 0.13) and more frequently had CCS
class III or IV angina (6.6% vs. 1.5%, p 5 0.009) at the latest
follow-up visit.
For patients initially treated with PI, the median incremen-
tal costs of subsequent need for a single intervention ($10,482),
more than one intervention ($16,384) or CABG ($22,809)
were high.
Finally, although models of actual costs rather than loge
cost were not as predictive, death during the follow-up period
was independently correlated with cost at both 12 months
($6,804 increment, p 5 0.06) and 36 months ($24,477 incre-
ment, p , 0.001).
Discussion
More than 1 million cardiac catheterizations are performed
annually in the United States (21) and the annual cost of caring
for patients with CAD in this country has been estimated to be
.$120 billion (2). These figures provide a potentially large
target for cost reduction initiatives. Intelligent resource utili-
zation requires insight into the determinants of cost over time
and understanding of the clinical effect of any cost reduction
measure. For the care of patients with CAD, major gaps exist
in our knowledge in both of these areas.
Previous studies. Factors related to the short- and long-
term costs after CABG (particularly, patient age, extent of
CAD and left ventricular dysfunction and postoperative com-
plications) (8,14) and the short-term costs of PI (particularly,
cardiac, renal and bleeding complications) and delays in
making the decision to perform the intervention (22) are well
studied. Data reflecting our knowledge of factors affecting
long-term costs after an initial strategy of either medical or
percutaneous treatments are very limited.
From the Randomized Intervention Treatment of Angina
(RITA) (3), Emory Angioplasty Surgery Trial (EAST) (23)
and the Bypass Angioplasty Revascularization Investigation
(BARI) (5) trials have come compelling evidence that al-
though initial costs are higher with CABG, in patients also
eligible for percutaneous transluminal coronary angioplasty,
costs associated with the latter equal or nearly equal those
associated with CABG over 2 to 4 years. Our data confirm this
finding in a practice-based rather than clinical trial-based
setting. Scant contemporary data exist allowing comparison of
medical with either surgical or interventional costs over time.
The results of the present study 1) reemphasize the impact
of the initial treatment strategy (medical therapy alone, PI or
CABG) on long-term cost, previously noted in more limited
analyses (12,15); 2) demonstrate that age and medical comor-
bidities have only a minimal effect, except for renal dysfunc-
tion, on cost over 3 years in this patient group; 3) underscore
the importance of late complications on cost; 4) highlight the
Table 7. Preprocedural Correlates of Three-Year Loge Cost*
Cost Effect
(%)† 95% CI
$
Increment
Multiple
p Value‡
Jeopardy score 10.9/U 8.1–13.7 4,117/U , 0.001
CAD 73.0 50.6–95.4 27,648 , 0.001
Baseline catheterization status 24.1/U 17.3–30.9 9,116/U 0.001
Baseline CHF 45.6 26.1–65.1 17,277 0.003
Baseline creatine $2 mg% 45.5 23.0–68.0 17,234 0.010
Valvular heart disease 29.6 11.2–48.0 11,196 0.047
*Constant 5 8.555; adjusted multiple r2 5 0.371. †See Appendix for
definition. ‡Univariate and multivariate p values for pretreatment variables
correlated with cost at an earlier follow-up time not entering this model:
arrhythmia indication, p 5 0.09, p 5 0.57; baseline angina class III/IV, p 5 0.009,
p 5 0.79; baseline positive stress test, p 5 0.001, p 5 0.17; baseline unstable
angina, p , 0.001, p 5 0.33; hospital transfer, p 5 0.10, p 5 0.50; myocardial
infarction ,2 weeks before initial catheterization, p 5 0.01, p 5 0.88; number of
diseased vessels at baseline, p , 0.001, p 5 0.27, prior bypass surgery at baseline,
p 5 0.16, p 5 0.82. Abbreviations as in Table 3.
Table 8. Overall Correlates of Three-Year Loge Cost*
Cost Effect
(%)† 95% CI
$
Increment
Multiple
p Value‡
Transplant recipient 212 198 to 226 80,262 , 0.001
Initial CABG 34.5 27.1 to 41.9 13,043 , 0.001
Initial medicinal Rx 219.8 223.4 to 216.2 27,485 , 0.001
Late CABG 62.3 51.7 to 72.9 23,581 , 0.001
Baseline unstable angina 18.5 13.7 to 23.3 7,020 , 0.001
Late admission 34.1 27.6 to 40.6 12,908 , 0.001
CAD 23.9 16.6 to 31.2 9,049 , 0.001
Baseline CHF 29.5 20.3 to 38.7 11,160 , 0.001
MI #2 wk before cath 19.9 14.1 to 25.7 7,528 , 0.001
Late percutaneous Rx 15.2 8.0 to 22.4 5,736 , 0.001
Arrhythmia indication 38.7 24.0 to 53.4 14,644 0.002
Diuretic Rx 14.2 8.8 to 19.6 5,392 0.004
Jeopardy score 4.0/U 2.6 to 5.4 1,519/U 0.004
Baseline creatinine $2 mg% 21.3 10.0 to 32.6 8,046 0.029
Antiarrhythmic Rx 14.9 6.5 to 23.3 5,630 0.042
*Constant 5 8.905; adjusted multiple r2 5 0.741. †See Appendix for
definition. ‡Univariate and multivariate p values for variable correlated with cost
at an earlier follow-up time not entering this model: baseline angina class III/IV,
p 5 0.009, p 5 0.34; baseline catheterization status, p , 0.001, p 5 0.96; baseline
left ventricular function, p , 0.001, p 5 0.90; baseline positive stress test, p 5
0.001, p 5 0.42; hospital transfer, p 5 0.10, p 5 0.90; use of cardiac rehabilita-
tion, p 5 0.02, p 5 0.23; valvular heart disease, p , 0.001, p 5 0.53.
Abbreviations as in Tables 1, 3 and 4.
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relatively diminutive role of outpatient pharmacy and rehabil-
itation costs on total cost; 5) suggest a cost-savings role for
stress testing before cardiac catheterization (at least for those
patients eventually requiring catheterization); and 6) docu-
ment the very low 3-year costs after catheterization showing
normal or nearly normal coronary arteries in patients with
previous functional test abnormalities.
Implications for cost analyses. Comparisons between
treatment strategies or providers must account for potential
differences in the characteristics of patients receiving treat-
ment. Both cardiac anatomy (e.g., “jeopardy score” or number
of diseased vessels) and functional status (degree of angina and
heart failure) were strongly associated with an increased 2- to
3-year cost in the present study. Furthermore, patients trans-
ferred from another hospital or with renal dysfunction had
augmented costs. Perhaps more surprisingly, treatment of
cardiac arrhythmia increased cost very considerably over time,
and factors such as age and diabetes mellitus were not dem-
onstrated to be particularly important over the time period
studied. (Given the very high costs after heart transplantation,
such patients should be considered separately.) Finally, these
data provide a framework for estimation of future costs given
known baseline patient or patient group characteristics, which
may be helpful to managed care organizations and their
contractors.
Implications for cost containment. The opportunities for
cost reduction suggested by these data are in many ways not
surprising, but for many, their relative magnitude has not
previously been revealed. For patients with CAD, the cost of
revascularization and clinical complications drive overall car-
diac costs. Any delay in performing revascularization or any
reduction in its cost or the cost of related complications will
result in substantial savings—if they are not offset by later
morbidity and cost. If these results can be generalized, and one
assumes that 50% of costs are variable (unpublished data,
Division of Finance, The Cleveland Clinic Foundation, 1994),
a 10% reduction in the cost of hospital stay for CABG, for
example, with a less invasive approach (24), could save ;$600
million annually in the United States alone. A treatment
reducing restenosis after PI by an absolute 10% would save
;$1.0 billion annually. Conversely, it would take at least a 50%
reduction of the cost of outpatient medications or from
referral to cardiac rehabilitation for the ;1 million patients
undergoing catheterization yearly to match these savings.
Finally, the savings engendered by the prevention or delay
of later myocardial infarction or cardiac death with treatments
such as CABG (25) or use of statin-class lipid-lowering agents
(26), measured either in dollars or quality of life, cannot be
ignored.
Limitations. Several limitations of this study should be
acknowledged: 1) the study reflects data from only a moderate-
sized, somewhat self-selected, cohort of patients from a single
institution over a relatively short period of time. Cost and
charges are recognized to vary, depending on hospital type and
location (10). A longer period of follow-up of more patients
and more care providers would be useful. 2) Costs associated
with newer therapies (e.g., stents placed without adjunctive
anticoagulation or use of new platelet inhibitors [6]) are not
fully considered. Treatment of CAD is rapidly evolving, and it
will always be difficult in such situations to have long-term data
that reflect contemporary treatment. 3) This study provides
something between a micro and macro clinical perspective.
Direct costs from bleeding requiring blood transfusion or
potential savings achievable by “streamlining patient care”
using critical care pathways cannot be ascertained. 4) Cardiac
rather than all medical costs were evaluated. Age and major
comorbidities might have had a larger impact were all costs
evaluated. 5) The perspective taken, that of the health care
provider, does not consider all costs to society (27,28).
These data provide a more comprehensive appraisal of the
determinants of cardiac cost in a heterogenous cohort of
patients with CAD over time than has previously been avail-
able. Their implications for prediction of patient costs and for
comparisons of providers and strategies of care are notable.
We gratefully acknowledge the expert technical support of Patti Durnwald in the
preparation of the manuscript.
Appendix
Statistical Equations and Variables Contributing
Independent Prognostic Information in
Subset Modeling
Equations:
Cost effect 5 Incremental cost/~Cost 2 Incremental cost!,
where
Incremental cost 5 exp~Constant 1 Coefficient! 2 exp ~Constant!,
and
Constant 5 Constant from regression equation 1 ~Incidence or meanx!
~Coefficientx! 1 ~Incidence or meany!~Coefficienty! 1 . . .,
where x,y are all covariates in the regression equation, except for the
variable being analyzed.
Percutaneous intervention versus coronary artery bypass surgery:
(In-hospital)/jeopardy score, congestive heart failure, catheterization
status; recent myocardial infarction, creatinine $2 mg%, angina class
III/IV, hospital transfer, patient age; (12 month)/congestive heart
failure, valvular heart disease, creatinine $2 mg%, catheterization
status; (36 month)/congestive heart failure, left ventricular ejection
fraction, catheterization status.
Medical versus percutaneous intervention: (In-hospital)/jeopardy
score, recent myocardial infarction, arrythmia indication, previous
bypass surgery, catheterization status, unstable angina, angina grade
III/IV, positive stress test, height; (12 months)/congestive heart failure,
valvular heart disease, recent myocardial infarction, catheterization
status, unstable angina, arrythmia indication; (36 months)/jeopardy
score, catheterization status, valvular heart disease.
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